Clinical data | |
---|---|
Other names | FKW-00GA; TGW00AA; TGW-00AA; TGWOOAA; TGW-OOAA |
Routes of administration | Oral[1] |
Drug class | Serotonin 5-HT1A receptor partial agonist; Serotonin 5-HT2A receptor antagonist[1][2] |
FKW00GA, also known as TGW00AA, is a serotonin 5-HT1A receptor partial agonist and serotonin 5-HT2A receptor antagonist which is under development for the treatment of generalized anxiety disorder, social phobia (social anxiety disorder), and sexual dysfunction.[1][3][2][4][5][6] It is taken by mouth.[1]
As of June 2021, FKW00GA is in phase 2 clinical trials for generalized anxiety disorder, social phobia, and sexual dysfunction.[1][3] It has been in phase 2 clinical trials since at least 2018.[6] The drug is under development by Fabre-Kramer Pharmaceuticals.[1][3][2] FKW00GA is a small molecule, but its chemical structure does not yet seem to have been released.[1][3]